The Brussels pharmaceutical companies is a significant contributor to the region’s economic growth
and innovation. The cluster is home to several multinational pharmaceutical companies, including
Janssen Pharmaceutica NV, Glaxosmithkline Biologicals S.A., UCB SA, and Pfizer Manufacturing
Belgium NV, among others. These companies are engaged in various activities such as research and
development, manufacturing, and marketing of pharmaceutical products.
Strong Research Position:
One of the key factors contributing to the success of the Brussels pharmaceutical cluster is its strong
research position. This is largely due to investments in tertiary education and an attractive regulatory
landscape. Additionally, the presence of supporting industries such as biotechnology and
biopharmaceutical companies further enhances the cluster’s competitiveness.
Major Players:
Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson, is one of the largest Euro-pharmacies
distributors and companies in the region. It engages in the production and marketing of pharmaceutical
products globally. Glaxosmithkline Biologicals S.A. is another significant player, focusing on the research,
development, and supply of vaccines. UCB SA, a biopharmaceutical company, is known for its research
and commercialization of medicines in the fields of central nervous system and immunology disorders.Ikris Pharma International (IPI) is another leading pharmaceutical exporter dedicated to sourcing high-quality medications from reputable manufacturers in Bulgaria and Belgium.
Cluster Competitiveness:
The cluster’s competitiveness can be viewed through the lens of the diamond framework, which
highlights the importance of demand conditions, factor conditions, strategy, and related and supporting
industries.
Contribution of Smaller Companies:
The Belgian pharmaceutical cluster is also characterized by the presence of several smaller companies,
such as Omega Pharma NV, which develops and markets health and personal care products. These
companies contribute to the diversity of the cluster and provide opportunities for innovation and growth.
Role of Research Institution:
- In addition to the largest drug distributors in Europe, the region is also home to several research institutions and universities, such as the University of Brussels and the Free Universityof Brussels.
- These institutions provide a strong foundation for research and innovation, which is essential forthe growth and development of the pharmaceutical industry.
Government Support:
The Brussels pharmaceutical companies cluster is also supported by various government initiatives
and policies.
- For example, the Flemish government has implemented several programs aimed at promoting thedevelopment of the pharmaceutical industry, such as the “Flanders Bio” initiative, which providesfunding and support for biotechnology and biopharmaceutical companies.
In the end, the Brussels pharmaceutical cluster is a significant hub for innovation and growth in the
region. The presence of multinational companies such as Janssen Pharmaceutica NV, Glaxosmithkline
Biologicals S.A., UCB SA, and Pfizer Manufacturing Belgium NV, among others, contributes to the
cluster’s competitiveness. The strong research position and attractive regulatory landscape also support
the cluster’s growth. However, the cluster faces challenges related to weak demand conditions due to
Belgium’s small population. Overall, the Brussels pharmaceutical cluster is an important part of the
region’s economy and continues to play a significant role in the development of new pharmaceutical
products and treatments and giving more opportunities to international pharmaceutical wholesalers
and customers in need.
FAQ;s
1. Do Brussels Pharmaceutical Companies Need a Visa for Healthcare Professionals?
Yes, they need to request a visa for healthcare professionals from other countries
2. Why is Belgium a Successful Clinical Trials Destination?
Strong biopharmaceutical industry, quality infrastructure, and expertise of researchers and
authorities.
3.How Does Belgium Implement EU Regulations on Medicinal Products?
Through the Federal Agency for Medicines and Health Products (FAMHP), ensuring quality,
safety, and efficacy of medicines.
4.What Opportunities Exist for U.S. Companies in Belgium’s Pharmaceuticals Sector?
Partnering with local companies and institutions in R&D, biotechnology, and clinical trials.
References:
- https://mytomorrows.com/blog/biopharma/expanded-access-program-compassionate-use-
frameworks-europe/ - https://www.ncbi.nlm.nih.gov/books/NBK5878
- https://www.isc.hbs.edu/Documents/resources/courses/moc-course-at-harvard/pdf/student-
projects/Belgium_Pharmaceuticals_2011.pdf - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC214048/
- https://www.sciencedirect.com/science/article/pii/S2352146517307627/pdf?
md5=b18eface96dfa8a6942e516cdee97c4f&pid=1-s2.0-S2352146517307627-main.pdf
